El interés en corto de Hubbell da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Hubbell. Los datos de interés en corto se actualizan cada dos semanas.

Hubbell (NYSE:HUBB) Bolsa, Informe de interés en corto

Hubbell

Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.

Hubbell Inc

Hubb Ventures Inc

Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.25 by 21.6 percent. This is a 45.56 percent decrease over earnings of $1.80 per share from the same period last year. The company reported quarterly sales of $145.89 million which missed the analyst consensus estimate of $168.50 million by 13.42 percent. This is a 13.13 percent decrease over sales of $167.93 million the same period last year.

Earnings

Earnings Misses

News

MBIN

Merchants Bancorp Q1 Adj. EPS $0.98 Misses $1.25 Estimate, Sales $145.89M Miss $168.50M Estimate

Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) raises FY2025 Adj EPS guidance from $6.60-$7.00 to $6.70-$7.10 vs $6.80 analyst estimate..

Guidance

Crown Holdings Raises FY2025 Adj EPS Guidance from $6.60-$7.00 to $6.70-$7.10 vs $6.80 Est

Cincinnati Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CINF#NASDAQ">CINF</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.62) by 61.29 percent. This is a 113.95 percent decrease over earnings of $1.72 per share from the same period last year.

Earnings Beats

CINF

Cincinnati Financial Q1 Adj. EPS $(0.24) Beats $(0.62) Estimate

EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. This is a 21.43 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $306.32 million which missed the analyst consensus estimate of $310.35 million by 1.30 percent. This is a 7.24 percent increase over sales of $285.64 million the same period last year.

EZPW

EZCORP Q2 Adj. EPS $0.34 Beats $0.31 Estimate, Sales $306.32M Miss $310.35M Estimate

Brixmor Property Group Q1 FFO $0.56 Beats $0.55 Estimate, Sales $337.51M Beat $330.03M Estimate

Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) affirms FY2025 sales outlook from $3.25 billion-$3.45 billion to $3.25 billion-$3.45 billion vs $3.53 billion estimate.

Noble Corp Affirms FY2025 Sales Guidance of $3.25B-$3.45B vs $3.53B Est

FWRG

First Watch Acquires 16 Franchise Restaurants In North And South Carolina For $49M

Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.31 by 9.68 percent. This is a 3.7 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $518.60 million which missed the analyst consensus estimate of $526.13 million by 1.43 percent. This is a 8.56 percent increase over sales of $477.70 million the same period last year.

UCTT

Ultra Clean Hldgs Q1 Adj. EPS $0.28 Misses $0.31 Estimate, Sales $518.60M Miss $526.13M Estimate

Northwest Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWBI#NASDAQ">NWBI</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.24 by 45.83 percent. This is a 52.17 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $127.82 million which beat the analyst consensus estimate of $112.32 million by 13.80 percent. This is a 23.81 percent increase over sales of $103.24 million the same period last year.

NWBI

Northwest Bancshares Q1 Adj. EPS $0.35 Beats $0.24 Estimate, Sales $127.82M Beat $112.32M Estimate

Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.50 by 12 percent. This is a 24.44 percent increase over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $166.66 million which beat the analyst consensus estimate of $162.86 million by 2.34 percent. This is a 24.76 percent increase over sales of $133.59 million the same period last year.

RMBS

Rambus Q1 GAAP EPS $0.56 Beats $0.50 Estimate, Sales $166.66M Beat $162.86M Estimate

Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate of $1.23 by 35.77 percent. This is a 63.73 percent increase over earnings of $1.02 per share from the same period last year. The company reported quarterly sales of $2.89 billion which beat the analyst consensus estimate of $2.82 billion by 2.42 percent. This is a 3.70 percent increase over sales of $2.78 billion the same period last year.

Crown Holdings Q1 Adj. EPS $1.67 Beats $1.23 Estimate, Sales $2.89B Beat $2.82B Estimate

Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) reported quarterly earnings of $0.26 per share which missed the analyst consensus estimate of $0.57 by 54.39 percent. This is a 42.22 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $874.49 million which beat the analyst consensus estimate of $873.87 million by 0.07 percent. This is a 37.26 percent increase over sales of $637.08 million the same period last year.

Noble Corp Q1 Adj. EPS $0.26 Misses $0.57 Estimate, Sales $874.49M Beat $873.87M Estimate

HomeStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMST#NASDAQ">HMST</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.07) by 114.29 percent. This is a 48.28 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $45.36 million which missed the analyst consensus estimate of $46.61 million by 2.69 percent. This is a 9.02 percent increase over sales of $41.60 million the same period last year.

HMST

HomeStreet Q1 Adj. EPS $(0.15) Misses $(0.07) Estimate, Sales $45.36M Miss $46.61M Estimate

Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) raises FY2025 FFO guidance from $1.27-$1.30 to $1.28-$1.30 vs $1.28 analyst estimate..

NTST

Netstreit Raises FY2025 FFO Guidance from $1.27-$1.30 to $1.28-$1.30 vs $1.28 Est

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) reported quarterly earnings of $3.42 per share which beat the analyst consensus estimate of $3.10 by 10.32 percent. This is a 17.53 percent increase over earnings of $2.91 per share from the same period last year. The company reported quarterly sales of $731.12 million which beat the analyst consensus estimate of $718.89 million by 1.70 percent. This is a 7.30 percent increase over sales of $681.35 million the same period last year.

FFIV

F5 Q2 Adj. EPS $3.42 Beats $3.10 Estimate, Sales $731.12M Beat $718.89M Estimate

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations will cover preclinical activity and safety data for STRO-004, the Company's novel exatecan Tissue Factor ADC, as well as showcase the unique advantages of Sutro's XpressCF+&#xAE; platform in enabling precise and efficient development of dual-payload ADCs.
"We are excited to share our progress advancing our next-generation ADC pipeline at AACR," said Jane Chung, Sutro's Chief Executive Officer. "In preclinical studies, STRO-004 consistently demonstrated potent, dose-dependent anti-tumor activity and a favorable safety profile across all tested doses. Of note, STRO-004, after only a single dose, achieved promising overall response and disease control rates in Tissue Factor-positive patient-derived xenograft models spanning multiple cancer types. We look forward to continuing to investigate the full potential of STRO-004, as we complete IND-enabling studies and prepare to initiate a first-in-human trial later this year."
Ms. Chung continued: "Also, as presented at AACR, our XpressCF+&#xAE; cell-free platform is uniquely capable of creating revolutionary dual-payload ADCs—differentiated by higher drug-to-antibody ratios, fully site-selective conjugation of two linker payloads and a validated, cell-free ADC manufacturing process. We are excited to showcase these and other key features of our platform, which enable our ADC candidates to overcome limitations of conventional ADCs and the challenges of targeting complex disease biology. These presentations further reinforce our technology leadership and our highly differentiated ADC candidates."

Biotech

General

STRO

Sutro Biopharma Announces Poster Presentations To Highlight Its Next-Generation Exatecan And Dual-Payload ADC Programs At Upcoming American Association for Cancer Research April 25-30 In Chicago, Illinois

Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) raises FY2025 FFO guidance from $4.79-$4.95 to $4.90-$5.04 vs $4.92 analyst estimate..

WELL

Welltower Raises FY2025 FFO Guidance from $4.79-$4.95 to $4.90-$5.04 vs $4.92 Est

Contracts

CWEN

MSFT

Clearway Signs 335 MW Power Purchase Agreement With Microsoft; Terms Not Disclosed

Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) raises FY2025 GAAP EPS guidance from $4.19-$4.29 to $4.21-$4.31 vs $4.42 analyst estimate..

CDNS

Cadence Design Systems Raises FY2025 GAAP EPS Guidance from $4.19-$4.29 to $4.21-$4.31 vs $4.42 Est

Tempest Therapeutics, Inc. - Common Stock

Comments

Hubbell

Interés en corto

Hubbell (NYSE:HUBB) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL